相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。A Randomized Phase II Study of Nivolumab Monotherapy or Nivolumab Combined with Ipilimumab in Patients with Advanced Gastrointestinal Stromal Tumors
Arun S. Singh et al.
CLINICAL CANCER RESEARCH (2022)
Phase II Randomized Study of CMB305 and Atezolizumab Compared With Atezolizumab Alone in Soft-Tissue Sarcomas Expressing NY-ESO-1
Sant P. Chawla et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Sintilimab, doxorubicin and ifosfamide (AI) as first-line treatment in patients with advanced soft tissue sarcoma: A single-arm phase
Z. Luo et al.
ANNALS OF ONCOLOGY (2021)
Cross-HLA targeting of intracellular oncoproteins with peptide-centric CARs
Mark Yarmarkovich et al.
NATURE (2021)
Case Report: Response to Regional Melphalan via Limb Infusion and Systemic PD1 Blockade in Recurrent Myxofibrosarcoma: A Report of 2 Cases
Edmund K. Bartlett et al.
FRONTIERS IN ONCOLOGY (2021)
GEMMK: A phase I study of gemcitabine (gem) and pembrolizumab (pem) in patients (pts) with leiomyosarcoma (LMS) and undifferentiated pleomorphic sarcoma UPS)
A. Smrke et al.
ANNALS OF ONCOLOGY (2021)
Phase II Study of Pembrolizumab in Combination with Doxorubicin in Metastatic and Unresectable Soft-Tissue Sarcoma
Michael B. Livingston et al.
CLINICAL CANCER RESEARCH (2021)
A phase 2 study of talimogene laherparepvec, nivolumab, and trabectedin (TNT) in advanced sarcoma.
Neal Shiv Chawla et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
A phase 1b study of avelumab plus DCC-3014, a potent and selective inhibitor of colony stimulating factor 1 receptor (CSF1R), in patients with advanced high-grade sarcoma.
Evan Rosenbaum et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
A phase II, open-label, randomized trial of durvalumab (D) with olaparib (O) or cediranib (C) in patients (pts) with leiomyosarcoma (LMS).
Olubukola Ayodele et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Phase II study of atezolizumab in advanced alveolar soft part sarcoma (ASPS).
Abdul Rafeh Naqash et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
High clinical activity of pembrolizumab in chordoma, alveolar soft part sarcoma (ASPS) and other rare sarcoma histotypes: The French AcSe pembrolizumab study from Unicancer.
Jean-Yves Blay et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Radiation-induced neoantigens broaden the immunotherapeutic window of cancers with low mutational loads
Danielle M. Lussier et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2021)
Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART)
Michael J. Wagner et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
Objective Response Rate Among Patients With Locally Advanced or Metastatic Sarcoma Treated With Talimogene Laherparepvec in Combination With Pembrolizumab A Phase 2 Clinical Trial
Ciara M. Kelly et al.
JAMA ONCOLOGY (2020)
Safety and clinical efficacy of toripalimab, a PD-1 mAb, in patients with advanced or recurrent malignancies in a phase I study
Jianliang Yang et al.
EUROPEAN JOURNAL OF CANCER (2020)
Phase II study of eribulin and pembrolizumab in patients (pts) with metastatic soft tissue sarcomas (STS): Report of LMS cohort.
Michael Nathenson et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Preliminary results of a phase II study of neoadjuvant checkpoint blockade for surgically resectable undifferentiated pleomorphic sarcoma (UPS) and dedifferentiated liposarcoma (DDLPS).
Christina Lynn Roland et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
A multicenter phase II study of nivolumab +/- ipilimumab for patients with metastatic sarcoma (Alliance A091401): Results of expansion cohorts.
James Lin Chen et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
A phase II single-arm study of nivolumab and ipilimumab (Nivo/Ipi) in previously treated classical Kaposi sarcoma (CKS).
Alona Zer et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
SAINT: Results of an expanded phase II study using safe amounts of ipilimumab (I), nivolumab (N), and trabectedin (T) as first-line treatment of advanced soft tissue sarcoma [NCT03138161].
Erlinda Maria Gordon et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Phase I dose escalation and expansion trial to assess the safety and efficacy of ADP-A2M4 SPEAR T cells in advanced solid tumors.
David S. Hong et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Activity and Safety of Geptanolimab (GB226) for Patients with Unresectable, Recurrent, or Metastatic Alveolar Soft Part Sarcoma: A Phase II, Single-arm Study
Yuankai Shi et al.
CLINICAL CANCER RESEARCH (2020)
CBFB-MYH11 fusion neoantigen enables T cell recognition and killing of acute myeloid leukemia
Melinda A. Biernacki et al.
JOURNAL OF CLINICAL INVESTIGATION (2020)
Assessment of Doxorubicin and Pembrolizumab in Patients With Advanced Anthracycline-Naive Sarcoma A Phase 1/2 Nonrandomized Clinical Trial
Seth M. Pollack et al.
JAMA ONCOLOGY (2020)
Nivolumab and sunitinib combination in advanced soft tissue sarcomas: a multicenter, single-arm, phase Ib/II trial
Javier Martin-Broto et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Characteristics of mismatch repair deficiency in sarcomas
Leona A. Doyle et al.
MODERN PATHOLOGY (2019)
Sarcomas in the United States: Recent trends and a call for improved staging
Michele M. Gage et al.
Oncotarget (2019)
Immunogenic neoantigens derived from gene fusions stimulate T cell responses
Wei Yang et al.
NATURE MEDICINE (2019)
MAGE-A3 Is a Clinically Relevant Target in Undifferentiated Pleomorphic Sarcoma/Myxofibrosarcoma
Anthony P. Conley et al.
CANCERS (2019)
First-in-Class, First-in-Human Study Evaluating LV305, a Dendritic-Cell Tropic Lentiviral Vector, in Sarcoma and Other Solid Tumors Expressing NY-ESO-1
Neeta Somaiah et al.
CLINICAL CANCER RESEARCH (2019)
T cell receptor-based cancer immunotherapy: Emerging efficacy and pathways of resistance
Smita S. Chandran et al.
IMMUNOLOGICAL REVIEWS (2019)
Axitinib plus pembrolizumab in patients with advanced sarcomas including alveolar soft-part sarcoma: a single-centre, single-arm, phase 2 trial
Breelyn A. Wilky et al.
LANCET ONCOLOGY (2019)
Systemic Interferon-γ Increases MHC Class I Expression and T-cell Infiltration in Cold Tumors: Results of a Phase 0 Clinical Trial
Shihong Zhang et al.
CANCER IMMUNOLOGY RESEARCH (2019)
Comprehensive immune characterization and T-cell receptor repertoire heterogeneity of retroperitoneal liposarcoma
Liang Yan et al.
CANCER SCIENCE (2019)
Systemic and local immunity following adoptive transfer of NY-ESO-1 SPEAR T cells in synovial sarcoma
Indu Ramachandran et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
A Pilot Trial of the Combination of Transgenic NY-ESO-1-reactive Adoptive Cellular Therapy with Dendritic Cell Vaccination with or without Ipilimumab
Theodore S. Nowicki et al.
CLINICAL CANCER RESEARCH (2019)
Cancer immunoediting and resistance to T cell-based immunotherapy
Jake S. O'Donnell et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2019)
Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials
Sandra P. D'Angelo et al.
LANCET ONCOLOGY (2018)
Immune profiles of desmoplastic small round cell tumor and synovial sarcoma suggest different immunotherapeutic susceptibility upfront compared to relapse specimens
Mary Frances Wedekind et al.
PEDIATRIC BLOOD & CANCER (2018)
Antitumor Activity Associated with Prolonged Persistence of Adoptively Transferred NY-ESO-1c259 T Cells in Synovial Sarcoma
Sandra P. D'Angelo et al.
CANCER DISCOVERY (2018)
PRAME and HLA Class I expression patterns make synovial sarcoma a suitable target for PRAME specific T-cell receptor gene therapy
Sietse J. Luk et al.
ONCOIMMUNOLOGY (2018)
Translocation-Related Sarcomas
Kenji Nakano et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
Combined KIT and CTLA-4 Blockade in Patients with Refractory GIST and Other Advanced Sarcomas: A Phase Ib Study of Dasatinib plus Ipilimumab
Sandra P. D'Angelo et al.
CLINICAL CANCER RESEARCH (2017)
Cancer-testis antigen expression in synovial sarcoma: NY-ESO-1, PRAME, MAGEA4, and MAGEA1
Kunio Iura et al.
HUMAN PATHOLOGY (2017)
Treatment of Patients With Metastatic Cancer Using a Major Histocompatibility Complex Class II-Restricted T-Cell Receptor Targeting the Cancer Germline Antigen MAGE-A3
Yong-Chen Lu et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial
Hussein A. Tawbi et al.
LANCET ONCOLOGY (2017)
MAGEA4 expression in bone and soft tissue tumors: its utility as a target for immunotherapy and diagnostic marker combined with NY-ESO-1
Kunio Iura et al.
VIRCHOWS ARCHIV (2017)
Characteristics and outcomes of patients with advanced sarcoma enrolled in early phase immunotherapy trials
Roman Groisberg et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2017)
Combination of pembrolizumab and metronomic cyclophosphamide in patients with advanced sarcomas and GIST: A French Sarcoma Group phase II trial
Maud Toulmonde et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Immunotherapy with Single Agent Nivolumab for Advanced Leiomyosarcoma of the Uterus: Results of a Phase 2 Study
Eytan Ben-Ami et al.
CANCER (2017)
Comprehensive adipocytic and neurogenic tissue microarray analysis of NY-ESO-1 expression - a promising immunotherapy target in malignant peripheral nerve sheath tumor and liposarcoma
Elizabeth Shurell et al.
ONCOTARGET (2016)
Prevalence of tumor-infiltrating lymphocytes and PD-L1 expression in the soft tissue sarcoma microenvironment
Sandra P. D'Angelo et al.
HUMAN PATHOLOGY (2015)
Randomized, open-label, multicenter, phase III study of eribulin versus dacarbazine in patients (pts) with leiomyosarcoma (LMS) and adipocytic sarcoma (ADI)
Patrick Schoffski et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
A Pilot Trial Using Lymphocytes Genetically Engineered with an NY-ESO-1-Reactive T-cell Receptor: Long-term Follow-up and Correlates with Response
Paul F. Robbins et al.
CLINICAL CANCER RESEARCH (2015)
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
Suzanne L. Topalian et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Expression of cancer-testis antigens MAGEA1, MAGEA3, ACRBP, PRAME, SSX2, and CTAG2 in myxoid and round cell liposarcoma
Jessica A. Hemminger et al.
MODERN PATHOLOGY (2014)
Comprehensive Genomic Analysis of Rhabdomyosarcoma Reveals a Landscape of Alterations Affecting a Common Genetic Axis in Fusion-Positive and Fusion-Negative Tumors
Jack F. Shern et al.
CANCER DISCOVERY (2014)
Oncology Meets Immunology: The Cancer-Immunity Cycle
Daniel S. Chen et al.
IMMUNITY (2013)
Cancer Regression and Neurological Toxicity Following Anti-MAGE-A3 TCR Gene Therapy
Richard A. Morgan et al.
JOURNAL OF IMMUNOTHERAPY (2013)
NY-ESO-1 is a sensitive and specific immunohistochemical marker for myxoid and round cell liposarcomas among related mesenchymal myxoid neoplasms
Jessica A. Hemminger et al.
MODERN PATHOLOGY (2013)
Safety and Tumor Responses with Lambrolizumab (Anti-PD-1) in Melanoma
Omid Hamid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
NY-ESO-1 is a ubiquitous immunotherapeutic target antigen for patients with myxoid/round cell liposarcoma
Seth M. Pollack et al.
CANCER (2012)
SYT-SSX breakpoint peptide vaccines in patients with synovial sarcoma: A study from the Japanese Musculoskeletal Oncology Group
Satoshi Kawaguchi et al.
CANCER SCIENCE (2012)
Tumor Regression in Patients With Metastatic Synovial Cell Sarcoma and Melanoma Using Genetically Engineered Lymphocytes Reactive With NY-ESO-1
Paul F. Robbins et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion
Robert D. Schreiber et al.
SCIENCE (2011)
Efficacy and Safety of Trabectedin in Patients With Advanced or Metastatic Liposarcoma or Leiomyosarcoma After Failure of Prior Anthracyclines and Ifosfamide: Results of a Randomized Phase II Study of Two Different Schedules
George D. Demetri et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Identification of heterogeneity among soft tissue sarcomas by gene expression profiles from different tumors
Keith M. Skubitz et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2008)
Immunotherapy with autologous dendritic cells and tumor-specific synthetic peptides for synovial sarcoma
A Matsuzaki et al.
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY (2002)
Pilot trial of tumor-specific peptide vaccination and continuous infusion interleukin-2 in patients with recurrent Ewing sarcoma and alveolar rhabdomyosarcoma: An inter-institute NIH study
R Dagher et al.
MEDICAL AND PEDIATRIC ONCOLOGY (2002)
Monophasic and biphasic synovial sarcomas abundantly express cancer/testis antigen NY-ESO-1 but not MAGE-A1 or CT7
AA Jungbluth et al.
INTERNATIONAL JOURNAL OF CANCER (2001)
分享论文
